Tranexamic Acid in Hip Fracture Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02736383|
Recruitment Status : Completed
First Posted : April 13, 2016
Last Update Posted : July 31, 2017
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||142 participants|
|Official Title:||Effectiveness of Tranexamic Acid (TXA) in Reducing Blood Loss in Hip Fracture Surgery|
|Actual Study Start Date :||May 2016|
|Actual Primary Completion Date :||July 2017|
|Actual Study Completion Date :||July 2017|
Patients that receive 2 gm TXA during surgery
No Tranexamic Acid
Patients that receive no TXA during surgery
- Blood Transfusion Rate [ Time Frame: 6 weeks ]Blood transfusion rates during the patients hospital stay will be assessed.
- Hospital Length of stay [ Time Frame: 6 weeks ]The patients length of stay in the hospital will be determined.
- Post operative complications [ Time Frame: 6 weeks ]Post operative complications will be assessed through the 6 weeks.
- Hospitalization costs [ Time Frame: 6 weeks ]Economic evaluation for inpatient and re-admission will be assessed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02736383
|Principal Investigator:||Blake W Miller, DO||Spectrum Health Hospitals|